The drug showed promising results in an international study involving nearly 2,400 participants, and the U.S. Food and Drug Administration is expected to make an approval decision for it in June ...

Ensitrelvir marks a breakthrough in anti-COVID treatment, paving the way for future defenses against betacoronaviruses.

Those who’ve dodged COVID-19 for more than four years may have a newly discovered immune response to thank. The results stem from a challenge trial: At the height of the pandemic in 2021, scientists ...

New study reveals how lingering spike protein in the brain's borders could explain long-term COVID-19 neurological symptoms and highlight vaccines' protective role. Study: Persistence of spike protein ...

Following a consultation with its emergency task force, the European Medicines Agency (EMA) has backed a drug for adult patients with acute respiratory distress syndrome (ARDS) induced by the SARS‑CoV ...

The “cicada” SARS-CoV-2 variant, which earned its nickname after staying relatively dormant following its discovery in 2024, has accounted for a small proportion of COVID-19 cases since the CDC began ...

Background Although health problems may persist beyond 4 weeks after SARS-CoV-2 infection, evidence on long-term ophthalmic ...